It marks the world’s first assessment of a leadless pacemaker delivering conduction pacing to the heart’s left bundle branch (LBB) area, Abbott says. CSP targets the LBB area by enabling pacing that mimics the heart’s natural electric rhythm.
Abbott completed the world’s first human leadless LBB area pacing (LBBAP) cases with Aveir in the study in December. The AVEIR CSP acute clinical feasibility study demonstrated successful implantation of the pacemaker deep into the wall separating the left and right chambers of the heart. Many achieved LBBAP. All patients received the Aveir ventricular (VR) leadless pacemaker at the end of the procedure.
CSP activates the left bundle branch area, enabling physiological pacing to mimic the heart’s natural electrical current. Integrating CSP procedures with leadless pacemaker technology could deliver unique benefits, Abbott says. Leadless systems eliminate the need for cardiac leads and an implanted pulse generator.
Data shared by Abbott demonstrated the safety and performance of the investigational Aveir CSP leadless pacemaker technology. Investigators presented findings at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego.
“For the first time, we have successfully demonstrated the feasibility of a leadless pacing system to facilitate conduction system pacing in the left bundle branch area of the heart, offering a novel approach to pacing therapy,” said Dr. Vivek Reddy, the study’s principal investigator. “Leadless pacing has already demonstrated significant benefits to patients. This new groundbreaking approach may enable a more physiologic way of stimulating the heart with Abbott’s AVEIR CSP leadless pacemaker system, giving patients more treatment options.”
More on the Abbott Aveir LBB pacing
Abbott says that, to maximize potential benefits, it has two unique approaches to CSP under development. These methods target the LBB area with both traditional pacing and leadless technology.
In addition to completing the AVEIR CSP acute feasibility study, it recently started enrolling patients in the ASCEND CSP pivotal clinical trial. This trial evaluates the safety and effectiveness of the investigational CSP implantable cardioverter defibrillator (ICD) lead. It looks at the lead at three months post-implant, enrolling up to 414 people across 70 global sites.
Abbott said the uniquely designed lead aims to reduce complications and enhance precision while improving long-term outcomes.
The company says its UltiPace pacing lead is the first FDA-approved, stylet-driven lead indicated for LBB area placement. Abbott recently received FDA breakthrough device designations for both Aveir CSP and the CSP ICD lead for LBBAP.
“Our ongoing innovation in conduction system pacing has the potential to drive meaningful advancements, offering new potential treatment options for people with slow or irregular heart rhythms,” said Randel Woodgrift, SVP of Abbott’s cardiac rhythm management business. “These two clinical studies underscore the critical importance of conduction system pacing in the left bundle branch area both with our breakthrough leadless technology and uniquely designed lead, enabling physicians to better treat a broader range of patients who require pacemaker and ICD therapies.”
